STCube announced on the 10th that patient dosing for phase 1b of the investigator-initiated phase 1b/2 clinical trial of ‘Nelmastobart’ for colorectal cancer has been completed. Since improvement ...

Immuno-oncology developer STCube is simultaneously conducting a third-party allotment paid-in capital increase worth 13 billion KRW and a shareholder preferential public offering paid-in capital ...

STCube announced on the 21st that it has received approval from the Ministry of Food and Drug Safety for the investigational new drug application (IND) for the immune anticancer candidate nelmastovat ...

Samsung Biologics announced Wednesday that it has signed a partnership deal with STCube for the development and manufacturing of STT-003, an anti-cancer immunotherapy candidate. STT-003, developed by ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

"Stage 4 colorectal cancer is a malignant condition that spreads to other organs such as lymph nodes, liver, and lungs, which most existing treatment methods fail to address. The survival period ...

Stcube (KQ:052020) Annual Report This summary provides an overview of the most significant critical numbers from each of the Stcube financial reports, including the Stcube income statement, balance ...

SONGDO, South Korea, July 12, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement ...

SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer ...

Samsung BioLogics said Tuesday that it has signed a contract development service agreement for STCube’s anticancer drug candidate. Under the agreement, Samsung BioLogics will lead cell line ...